A2 Biotherapeutics

What A2 Biotherapeutics does

A2 Biotherapeutics is a clinical-stage biopharmaceutical company developing precision cell therapies for solid tumors. Founded in 2018 and headquartered in Agoura Hills, California, the company operates as a privately held venture-backed entity with 101-250 employees. Its proprietary Tmod™ technology platform enables logic-gated CAR T-cell therapies that selectively target tumor cells using a dual-receptor architecture: an activator receptor recognizing tumor antigens (e.g., mesothelin/MSLN) and an inhibitory receptor detecting HLA-A*02 on normal cells, so that T-cells kill only when the inhibitory signal is absent. The platform is intended to overcome the on-target/off-tumor toxicity that has historically limited CAR-T use in solid tumors.

The company's clinical pipeline is anchored by two autologous CAR T-cell programs evaluated under the Phase 1/2 EVEREST-2 master protocol. A2B694 is the first-generation Tmod™ construct; initial data presented in November 2025 included the first reported complete response to CAR T-cell therapy in a patient with metastatic non-small cell lung cancer, with nine patients enrolled and no dose-limiting toxicities as of September 2025. A2B543 is the second-generation candidate, enhanced with a membrane-tethered IL-12 booster designed to localize T-cell potency gains to the tumor microenvironment while limiting systemic IL-12 toxicity. A2B543 received FDA IND clearance in January 2026, first patient dosing in February 2026, and FDA Fast Track designation in April 2026. Both programs target MSLN-expressing solid tumors in germline heterozygous HLA-A*02 adults across colorectal, pancreatic, lung, ovarian cancers, and mesothelioma.

A2 Biotherapeutics is pre-revenue and generates no product or licensing income today; revenue is contingent on future regulatory approval and commercialization. Capital has been raised exclusively through venture equity across at least six disclosed rounds (most recent: $80M Series C in January 2025 led by The Column Group and Samsara BioCapital) plus a $300,000 G-Rex® manufacturing grant from the ScaleReady consortium. The current go-to-market motion is clinical execution rather than commercial sales; future commercialization is expected through specialty oncology distribution channels and potential large-pharma partnerships, with the company also evaluating the G-Rex® manufacturing platform for scalable autologous CAR-T production.

Name

A2 Biotherapeutics

Legal name

A2 Biotherapeutics Inc.

Website

https://a2bio.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

101–250 employees

Short description

A2 Biotherapeutics is a clinical-stage biopharmaceutical company developing logic-gated autologous CAR T-cell therapies using its proprietary Tmod™ platform to selectively target solid tumors expressing mesothelin in HLA-A*02 heterozygous adults across NSCLC, colorectal, pancreatic, ovarian, and mesothelioma indications.

Ownership category

akta.pro rank

Product category

Clinical-Stage Cell Therapy Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industries

Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• CAR T-cell therapy
• Solid tumor treatment
• Logic-gated cell therapy
• Precision oncology
• Cell therapy platform

Headquarters

HQ city

Agoura Hills

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure

Revenue model

1. Clinical Stage Development: Pre-revenue clinical stage biotech company developing CAR T-cell therapies for solid tumors. Revenue generation expected upon FDA approval and commercialization of pipeline therapies.
2. Future Therapeutic Licensing: Potential licensing agreements with pharmaceutical partners for co-development and commercialization of CAR T-cell therapies in various global markets.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

A2 Biotherapeutics is a clinical-stage biopharmaceutical company developing logic-gated CAR T-cell therapies for solid tumors. Its lead candidates, A2B543 and A2B694, use the proprietary Tmod™ platform to selectively target mesothelin-expressing tumor cells while sparing normal tissue. The company operates from Agoura Hills, California and is advancing its pipeline through clinical trials in oncology.

Product overview

A2 Biotherapeutics is a clinical-stage biopharmaceutical company developing precision cell therapies using its proprietary Tmod™ technology platform. The company's core products include A2B543 and A2B694, which are logic-gated CAR T-cell therapies designed to target solid tumors expressing mesothelin while addressing the immunosuppressive tumor microenvironment through membrane-tethered IL-12 booster technology. These therapies are being evaluated in the ongoing EVEREST-2 Phase 1/2 clinical study across multiple solid tumor types including colorectal, pancreatic, lung, ovarian cancers, and mesothelioma. The company is also evaluating the G-Rex® manufacturing platform for scalable production of its CAR-T therapies.

Differentiator

Problem solved

Functional benefit

Brands

• Tmod™: Proprietary technology platform for logic-gated CAR T-cell therapies developed by A2 Biotherapeutics.

Products and services

• A2B543
• A2B694

Quantifiable outcome

• First complete response reported in a patient with metastatic NSCLC treated with A2B694 CAR T-cell therapy
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• ScaleReady (Wilson Wolf, Bio-Techne Corporation, CellReady)coreStrategic or Co-development Partner · 6 May 2025Consortium of cell therapy manufacturing technology providers awarded A2 Biotherapeutics a $300,000 G-Rex® Grant to evaluate the G-Rex platform and G-CART process for CAR-T therapy production targeting solid tumor indications. Represents strategic collaboration for scalable manufacturing technology.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Allogene Therapeutics: Clinical-stage cell therapy company developing allogeneic CAR-T therapies for hematologic and solid tumors. Comparable as a CAR-T platform company with broader pipeline but competing in the same modality space.
• Adaptimmune Therapeutics: Clinical-stage cell therapy company developing TCR-T cell therapies for solid tumors, including SPEAR T-cells targeting MAGE-A4 and other antigens. Direct competitor to A2 Biotherapeutics in solid tumor cell therapy with similar autologous manufacturing approach.
• Lyell Immunopharma: Clinical-stage cell therapy company focused on solid tumor CAR-T and TIL therapies, with proprietary technology to overcome T-cell exhaustion. Comparable in solid tumor CAR-T focus and clinical-stage profile.
• Caribou Biosciences: Clinical-stage cell therapy company developing allogeneic CAR-T cell therapies using CRISPR gene editing. Comparable as a CAR-T platform company pursuing off-the-shelf approaches for hematologic and solid tumors.
• Nkarta: Clinical-stage cell therapy company developing allogeneic and autologous CAR-NK cell therapies for solid tumors and hematologic malignancies. Comparable in solid tumor cell therapy focus and engineering approach.
• Immatics: Clinical-stage immunotherapy company developing TCR-T and TCR-bispecific therapies for solid tumors, with a similar precision-targeting approach. Directly comparable in target market (solid tumor cell therapy) and modality (engineered T-cell receptors).
• Precision BioSciences: Clinical-stage cell therapy company developing allogeneic CAR-T therapies using ARCUS gene editing. Comparable as a CAR-T platform peer targeting oncology indications with similar clinical-stage profile.
• Fate Therapeutics: Clinical-stage cell therapy company developing off-the-shelf iPSC-derived NK and T-cell therapies for cancer. Comparable in cell therapy modality and oncology focus, though pursuing allogeneic rather than autologous approach.

Broad incumbents

• Bristol Myers Squibb: Large pharmaceutical company with approved CAR-T therapies (Breyanzi, Abecma) and active solid tumor cell therapy pipeline. Represents a potential strategic acquirer or partner and a broader benchmark for cell therapy commercialization.
• Iovance Biotherapeutics: Commercial-stage cell therapy company with FDA-approved TIL therapy (Amtagvi) for solid tumors. Comparable in solid tumor cell therapy focus with broader portfolio and established commercial infrastructure.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/a2-biotherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds6 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about A2 Biotherapeutics